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The objective of multivariate Design of
Experiments (DoE) is to yield statistically
significant (not necessarily equivalent to
scientifically correct) answers, only in situations
where those multiple questions (factors) are
stochastic and function independently of each
other. In addition, the sparsity of effects
principle is implicit in DoE, it being assumed
that higher order ($ 3) factor interactions are
insignificant in affecting the response
variable(s). However, most unforeseen
interactions involving excipients in
pharmaceutical processes proceed via insidious
cascading mechanisms with the response
variable affected only when all these factors are
sequentially or simultaneously present and/or
activated. Furthermore, even non-sequential
multifactorial events, i.e., those that ordinarily
would not cause undesirable reactions under
Markovian conditions, can affect the response
variable(s) due to the equilibrium nature of
chemical processes; even when reactions can be
driven far to the product side. Some examples
of such equilibrium conditions that can occur in
pharmaceutical processes are:
1. The ratio of non-ionized to ionized,
deprotonated to protonated, non-micellized
to micellized, API/excipient/buffer species.
2. The ratio of ionized to non-ionized,
ionizable substituent/functional groups on
polymeric backbones.
3. The ratio of solvated to non-solvated
polymer chains.
4. The ratio of glassy (amorphous) to
crystalline regions in (freeze dried) or
processed API or excipient polymers.
5. The ratio of multiple protein and/or peptide
quaternary structures.
These ratios are determined by Le-Chatelier’s
principle, including the common ion effect, and
equilibrium constants, which are in turn
dependent on temperature, pressure, pH,
chemical interactions and known and unknown
raw material attributes. The ratios affect ion-
pair and hydrophobic interactions, buffer
capacity, solubility and precipitation,
emulsification or micellization capacity,
degradation kinetics/pathways, adsorption to
and extraction of (plasticizers, antioxidants,
lubricants etc.) from manufacturing materials
and/or other excipients/APIs/primary
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packaging containers, propensity and
magnitude of re-dox reactions, sub-micellar
association, and a variety of other factors that
can affect CQAs. In the absence of a
knowledge of the reaction mechanisms, a mere
probabilistic absence of DoE response, even on
multiple occasions, does not constitute
evidence that such a response will never occur.
Ironically, process optimization to minimize a
‘known’ risk may ‘activate’ other factors that
may exacerbate or precipitate other ‘unknown’
risks. Borrowing jargon from the biochemical
field, factor(s) may be sufficient, but not
necessary, to affect the response variable(s); or,
factor(s) may be necessary, but not sufficient, to
affect the response variable(s). The
(manifestations of those) factors themselves
may behave non-linearly or discontinuously
even within the design space (critical micelle
concentrations, cloud points, association
constants, ion-pair interactions, equilibrium
constants, solubility product, adsorption
kinetics etc.) which makes the definition of a
design space much more challenging than that
portrayed by DoE responses alone.
Complex macromolecular excipients may
possess sub-populations whose chemical
attributes differ significantly from the averages
(and also between lots and suppliers) on which
compliance to compendial specifications is
based. Furthermore, ‘non-compendial’ material
attributes may manifest in erratic fashion
depending on their interaction with other
known or unknown excipient or API material
attributes or process parameters. Due to the
complexity of excipients, and attribute
dependence on manufacturing history/
processes, many users may not be aware of true
variability or non-compendial attributes. The
intermolecular weight between cross-links, the
posit ional  randomness of glyceride
poly(ethoxylation) or that of multiple residual
functional groups on a polymer backbone, the
length of a ‘block’ in a block co-polymer, the
ratio of different sugars in a polymer backbone
or the degree of branching, the molar
substitution, polydispersity, differing ratios of
hydrophobic or hydrophil ic species
subpopulations in hydrophilic or hydrophobic
amphiphilic molecules represent a small
sampling of such attributes. Identification of
CMAs and CPPs’ from a DoE performed on
the upper and lower specification limits of
nominal compendial specifications of
macromolecular excipients is inherently
probabilistic because each experimental design
point itself embeds a bell curve of unknown
standard deviation of undefined chemical
attributes. What may be “non-critical” today
may suddenly become critical tomorrow even
with the same excipient specifications in the
same design space.
Finally, the adage of ‘correlation not being
equivalent to causation’ is eminently germane to
the current practice of using DoE responses
alone as measures of criticality with little or no
mechanism based understanding. Furthermore,
those responses are generated from subjectively
chosen attributes regardless of or without
sufficient knowledge as to whether there exist
chemical and/or mechanical mechanism(s) (of
failure, reaction, interaction) associated with
those attributes. 
 
These immensely complex considerations often
make DoE (the most widely accepted surrogate
for QbD), or any risk analysis and mitigation
efforts based on misguided or the common-
denominator compliance application of DoE
alone, irrelevant to a vast array of multifactorial
pharmaceutical processes, which are neither
stochastic (even across a single unit operation)
nor single (or even multiple) factor cause-effect
isolable. The compliance driven, algorithmic
compression of QbD leads to a flawed model
that is hard pressed to improve, build in quality,
or minimize rejection rates in pharmaceutical
processes.
These caveats are lost on the legions of
technicians who labor in designing and
performing experiments and in proclaiming the
problem to be solved or the risk to be mitigated
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based on software generated Pareto values and
interaction coefficients, until the same problem
surfaces again in another batch. The fascination
with DoE as a surrogate QbD panacea rests on
the non-necessity of possessing any prior
chemical, physical or engineering knowledge,
the almost certain ‘identification’ of the
‘contributory factor(s)’ affecting the response
variable(s) and last, but not the least, having
mathematically verifiable and reviewable
content to fill out the QbD modules of
regulatory submissions, and satisfy regulatory
compliance requirements.
One of the more indiscriminate uses (and there
are many) of factorial design is to include
almost every variable in the process and run a
DoE representing the culmination of a process
where a ‘compliance convenient’ disconnect
exists between the ‘why’ and the ‘how to’;
between mechanisms and statistical probability.
A list of purported ‘mechanisms’ that appear in
regulatory submissions would probably not be
worthy even of inclusion in ‘Mechanisms for
dummies’, encompassing such verbiage as
‘decrease in solubility’, ‘change in pH’, ‘increase
in number of particulates’ etc. These scenarios
occur with significantly more (alarming)
regularity than erudition would lead one to
believe. In an example typical of (say) a
polymeric excipient, the modus operendi would be
to run a DoE on a ‘catch all’  list of ‘critical
process parameters’ and ‘critical material
attributes’ that ‘affect’ one or several release
and shelf life specifications of the product that
the polymer is a constituent of. Some of these
attributes would include the following, in part,
because they are macro-visible steps of the
process and therefore easily intuitively
envisaged as having ‘something to do’ with
process criticality:
• Viscosity of polymer (per the certificate of
analysis from the excipient manufacturer)
• pH of polymer (fixed concentration in water, per
the certificate of analysis from the excipient
manufacturer)
• Temperature of water used to disperse/dissolve
the polymer
• Time of dispersion/dissolution of polymer
• Concentration of polymer
• Filtration speed
• Pore size, surface/volume ratio of filter/ filter
train
• Temperature/volume of rinse water 
• Bulk sterilization F0
• Bulk sterilization time to reach 121EC
• Bulk sterilization time to cool down from 121EC
to room temperature (RT) (chilled water or RT
water in jacket)
• Mixing speed
The ‘design space’ would then be constructed,
usually from a fractional factorial design of
experiments, based on the software calculated
‘critical process parameters’, associated software
generated numbers and the magnitude to which
each CPP affects the response variable(s).
Implementation of such simplistic models is
perhaps implicitly encouraged by regulatory
submission requirements which prefer the
presentation of data in a statistically quantifiable
‘clean’ format , place the onus of process
knowledge and understanding on the
manufacturer and assume that the manufacturer
is desirous of improving process capability and
product quality. Akin to aviation parlance,
where ‘any landing which you can walk away
from is a good landing’, in pharmaceutical
processes, any process which consistently
produces a product that meets release
specifications is a good process and is generally
embraced as such by a risk-averse
pharmaceutical industry. The question then is
why a pharmaceutical manufacturer would want
to improve product/process quality for its own
sake in the absence of a history of batch failures
(although not in the frequency of deviation
reports) and (in the presence of) exclusivity of
excipient/API supply agreements (more on this
below).
What is needed is a mechanism based approach to
identify and minimize risk, on an ongoing basis,
that addresses the following questions:
1. Why is this a risk?
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2. What is/are the chemical, physical and
engineering mechanism(s) by which this
risk is manifested?
3. Are these mechanisms only able to be
altered or mitigated by adjusting the CMAs’
or CPPs’, or do these and other attributes
that are not listed on the certificate of
analysis and/or the USP/NF monographs
change these risk/chemical, physical and
engineering mechanisms as well? Can these
attributes or their interactions change within
the confines of the design space (see
point 5)
4. What is the probability and magnitude of
this risk being exacerbated or mitigated by
other risk factors; in other words, can
different individual low risk mechanisms
interact to form a significantly larger risk or
vice-versa?  (detectability)
5. Can this risk be adequately modeled by a
stochastic DoE? Will the magnitude of the
effect of the CPPs’ on the response
variable(s) (severity) remain the same no
matter where the process operates within
the design space? 
6. Can this risk be intentionally precipitated /
activated by deliberate application of one
or a combination of simultaneous,
sequential or non-sequential; monograph
or non-monograph attributes within the
confines of the design space thus validating
the risk mechanism(s)?
In this context, the ICH definition of criticality
can recommend a ‘mechanisms based’
categorization into the ‘detectable’, ‘severe’ and
‘probable’. The more explicit mechanisms that
can be listed for an unfavorable event, the less
is the subjectivity in assigning risk. ‘Unknown-
unknowns’ arise in part due to an inadequate
understanding of the mechanisms, nature and
magnitude of chemical, physical and/or
engineering interactions and/or due to their,
deliberate, chance or benighted, decoupling or
obfuscation from the (already pharmaceutically
inapplicable) DoE statistical model in pursuit of
regulatory approval. To state that there will
always be ‘unknowns’ in a pharmaceutical
process that no good statistical design can
foresee may be true to a certain extent but must
not serve as an excuse not to fully and
thoroughly understand the chemistry, physics
and engineering of the process. The ‘black
swan’ unforeseen event rationalized by
hindsight has a greater probability of being predicted
beforehand by a mechanism based process
understanding that accounts for more relevant
data during risk assessment with the
consequent identification of the design sub-
space where these event may occur. 
In this brute-algorithmic-force world, where the
number of mathematical operations is not rate-
limiting, it has become anathema to suggest that
not all processes/problems are algorithmically
compressible. Manuscripts in this journal have
addressed the concern that innovation and/or
quality control is being increasingly driven to
compliance satisfying ends and not toward an
increased understanding of nature or
pharmaceutical processes. Nobody wants
CQAs’ to fail specifications and batches to be
dumped in bulk. However, the necessity of
achieving 6σ process capability, especially when
the historical rate of batch failure is low enough
to  be  f inanc i a l l y  manageab l e ,  i s
(understandably) lost on manufacturing
facilities where understanding how and why a
process works the way it does or tightening
process or product specifications seldom
affects product in vivo efficacy and does not
proportionately increase the elasticity of
demand. When dealing with a clinical trial stage
new product or process that has no or little
historical precedent, a significantly greater
rejection rate can be tolerated by the CMO
and/or innovator because of access to, and
ability to raise capital from speculative financial
markets. By the time an NDA or BLA is ready
for filing, enough ‘trial and error’ data has been
generated on batches to enable writing of QbD
modules in regulatory dossiers. A concerted,
focused and intentional strategy of process risk
minimization, by chance or design,  may hence
fall by the wayside with little or no impetus for
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Figure 1 Schematic representation of challenges in using
algorithmic DoE as a QbD heuristic
resurrection. A regulatory approach that allows
for an ongoing post market assessment and
mitigation of risk may be of much utility in
getting pharmaceutical manufacturers to
understand their processes better. This concept
of continuous verification has been espoused in
the most recent FDA process validation
guideline. The conceptualization of risk, not as
a temporal static entity, but of something that
evolves over time can do much to eliminate the
‘one shot and done’ mentality of NDA or BLA
filers of QbD modules. But more than that, the
visualization of risk as a time dependent
concept changes the thought paradigm from a
futile mismatching exercise of unsuitable
mathematical algorithms with a smorgasbord of
subjectively chosen process parameters or
material attributes, to one of a mechanism
based scientifically relevant sound approach. A
mechanism based assignment of effect(s) to
cause(s) is likely to be an inherently greater
incentivizer of process understanding than an
unsuited algorithmic statistical one.  
All statistical models are probabilistic. Much
more so is a statistical, stochastic, higher order
interaction and mechanism invariant model that
is made even more irrelevant as a predictor of
CQAs’ when only the more obvious
‘compliance convenient’ factors are used to
interrogate the chemical process. The
probability of unfavorable effects on CQAs’
and/or the response variable occurring in such
a ‘design space’ is consequently significantly
greater than is observed. Small wonder then
that the need for ‘deviation reports’ has
continued to proliferate for pharmaceutical
processes even in the presence of the purported
advantages of a ‘flexible’ design space that
supposedly has the ability to produce a product
that consistently meets design/release
specifications.  The identification of molecular
mechanisms does not necessarily require
empirical experimentation but does require a
considerable degree of expertise in chemistry,
physics and engineering. For a given
mechanism, CPPs’ or CMAs’ (compendial or
non-compendial for API, excipients and
primary packaging components) or their
specific combinations (whether within or
outside the design space) where the undesirable
effect on the CQA will occur can be predicted
significantly more precisely and accurately than
can with DoE. Mechanism based risk
prediction is manufacturer, manufacturing lot
and supply chain invariant i.e. the identification
of the (non-detrimental to CQAs’) design sub-
space only requires a knowledge of the CMAs’
and the CPPs’ (illustrated in Figure 1). 
A mechanism based approach to minimizing
trivial or non-trivial undesirable effects on
CQAs’ and/or response variable(s) is what
should drive the optimization of the ‘design
space’. A competent coach will assign players to
their maximum positional capability (and
advantage) in the soccer field (design space)
that is not necessarily based only on historical
position-specific statistics (a player may not be
competent at the position he/she occupies not
because of positional inadequacy but because
other players are mismatched or incompetent at
their positions). 
“You must want it”; is my response to my first
question of the year to students in my class, the
question being: What is the most important
characteristic of learning and/or of education?
The premise of the current iteration of QbD
focusing unduly on canned compliance using an
unsuitable statistical model, of not adding
anything to the bottom line, of not rewarding
better processes and quality and not lending
itself to the scientific building of quality into the
product does not make it a particularly desirable
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entity for adoption, is not entirely unjustified in
this regard, and seems to be the proverbial case
of good intentions gone awry. The current
flawed model of QbD may actually incentivize
the adoption of the folksy aphorism: ‘if it ain’t
broke, don’t fix it’, because the model is
unsuited for predicting non-trivial cause-effect
relationships in multifactorial, non-stochastic,
chemical reactions or physicochemical and
engineering processes thereby significantly
undermining its usefulness in consistently
preventing undesirable effects on CQAs’
and/or the response variable(s), its application
involves the subjective choice of, and
assignment of arbitrary criticality to,
‘compliance convenient’ obvious process
parameters, its assessment in terms of
regulatory rubric encourages over-simplification
and reliance on mathematical algorithms
disconnected with reaction mechanisms,
kinetics, thermodynamics and equilibrium and
it promotes complacence via its overtly
optimistic probabilistic designation of a ‘design
space’.   
The author has had the good fortune and
opportunity to witness and solve many non-
trivial chemical process related problems
firsthand including some that required no less
than three CMA and CPP related attributes,
some non-compendial, to be simultaneously
present/activated. Not one of those was
predicted or solved (or could have been capable
of being predicted or solved) using the current
DoE iteration of QbD. All could have been
predicted with a mechanism based approach.
Nevertheless, the status-quo of paying lip
service to QbD persists and countless man-
hours are devoted to conjuring up CPPs’,
CMAs’ and a ‘design space’ for regulatory
submissions. It is ironical to note that
pharmaceutical companies have to resort to
‘outside’ consultants on a regular basis to solve
or predict process related problems on a not
irregular basis. Has the pharmaceutical industry
adopted QbD out of choice or because of
regulatory coercion?  So long as pressure on
(already generous) profit margins (due to
manufacturing defects or batch failures) can
continue to be alleviated by either a value added
or patent extensible product pipeline, there will
be little or no financial incentive to genuinely
adopt the current unsuitable iteration of QbD.
So long as there is tacit realization that a DoE
generated flexible ‘design space’ does not
significantly improve quality, has little or no
influence on the frequency of black-swan
unfavorable events and is just as probabilistic as
the earlier ‘3 batch’ version of QbD, there will
be little financial, scientific or innovation driven
impetus to adopt the current unsuitable version.
There is a danger that QbD, as currently
enforced, interpreted and practiced, will
become another acronym associated with the
cost of doing business.
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